HIV and pregnancy · Lancet HIV · 2021
Summary: an HIV drug’s brain-and-spine defect risk is at most 0.10%. Its own numbers give 0.99%.
Defect rate, % of pregnancies: what 0 cases in 384 allows, and earlier studies
The paper says
In Brazil, none of 384 pregnancies in which the mother was taking the HIV drug dolutegravir at conception showed a brain or spine defect. Zero cases can’t prove zero risk, so the summary gives a range for the true rate: 0% to 0.10%.
Its own data show
The paper names the standard formula it used. For no cases in 384 it gives 3.84 ÷ (384 + 3.84) = 0.99%, nearly ten times the summary’s 0.10%. The same formula matches every other such range in the paper, like 0% to 0.36% for no cases in 1,068 pregnancies on another HIV drug.
A range’s top end is the highest rate the data can’t rule out, and zero cases prove little: even if 0.4% of pregnancies were affected, 384 would show none about 1 time in 5. As printed, the study’s main result seems to rule out all five rates earlier studies found for this drug; corrected, it includes four.